Literature DB >> 2289198

Opposing influence of age on the growth and colony-forming ability of mouse melanoma B16 and mammary adenocarcinoma: correlation with natural killer activity.

J Gabrilovac1, M Radacić, M Osmak, M Boranić.   

Abstract

C57B1 and CBA mice of different ages (6, 12, 26 or 35 weeks) received intramuscular inocula of melanoma B16 or mammary adenocarcinoma (MCa), respectively. Median survival time was shorter, the younger the recipients. Tumor enlargement was correspondingly retarded in older mice. This was associated with decrease of natural killer (NK) activity in the spleens. However, the cytotoxicity against fresh syngeneic tumor cells, increased with age in CBA mice. In contrast to the growth of intramuscular tumors, the ability of intravenously injected B16 or MCa cells to form nodules in the lungs was significantly superior in old animals (35 weeks or more), with low levels of NK activity, than in young ones (6 weeks) with high levels of NK activity. Stimulation of NK activity by poly(I).poly(C) reduced the number of MCa colonies by 50% in the lungs of old mice, but had no effect on colony-forming ability in young animals. The observed association of tumor growth with age and NK activity levels may reflect (a) an interplay of tumor-inhibiting and tumor-promoting effects of NK cells, changing with age, and (b) the accessibility of tumor cells, inoculated intramuscularly or captured in the lungs, to these influences.

Entities:  

Mesh:

Year:  1990        PMID: 2289198     DOI: 10.1007/bf01741723

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  20 in total

1.  Role of lymphokine-activated killer cells as mediators of veto and natural suppression.

Authors:  E Azuma; J Kaplan
Journal:  J Immunol       Date:  1988-10-15       Impact factor: 5.422

2.  A direct relationship between immune competence and the subcutaneous growth rate of a malignant murine lung tumor.

Authors:  J M Yuhas; N H Pazmino; J O Proctor; R E Toya
Journal:  Cancer Res       Date:  1974-04       Impact factor: 12.701

3.  Enhancement of tumor growth by suppressor factors derived from a natural suppressor/cytotoxic cell line.

Authors:  W Y Almawi; B L Pope
Journal:  Transplantation       Date:  1988-05       Impact factor: 4.939

4.  Transfer of age-associated restrained tumor growth in mice by old-to-young bone marrow transplantation.

Authors:  W B Ershler; A L Moore; H Shore; R L Gamelli
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

5.  B16 murine melanoma and aging: slower growth and longer survival in old mice.

Authors:  W B Ershler; J A Stewart; M P Hacker; A L Moore; B H Tindle
Journal:  J Natl Cancer Inst       Date:  1984-01       Impact factor: 13.506

6.  The immune reaction as a stimulator of tumor growth.

Authors:  R T Prehn
Journal:  Science       Date:  1972-04-14       Impact factor: 47.728

7.  Role of the thymus and T-cells in slow growth of B16 melanoma in old mice.

Authors:  T Tsuda; Y T Kim; G W Siskind; A DeBlasio; R Schwab; W Ershler; M E Weksler
Journal:  Cancer Res       Date:  1987-06-15       Impact factor: 12.701

8.  Lysis of fresh murine mammary tumor cells by syngeneic natural killer cells and lymphokine-activated killer cells.

Authors:  I H Ames; C E Gates; A M Garcia; P A John; A K Hennig; R H Tomar
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

9.  Role of natural killer cells in the destruction of circulating tumor emboli.

Authors:  N Hanna; I J Fidler
Journal:  J Natl Cancer Inst       Date:  1980-10       Impact factor: 13.506

10.  Interferon-gamma treatment of B16 melanoma cells: opposing effects for non-adaptive and adaptive immune defense and its reflection by metastatic spread.

Authors:  M Zöller; A Strubel; G Hämmerling; G Andrighetto; A Raz; A Ben-Ze'ev
Journal:  Int J Cancer       Date:  1988-02-15       Impact factor: 7.396

View more
  1 in total

1.  Further characterization of a clinically relevant model of melanoma metastasis and an effective vaccine.

Authors:  D Shrayer; H Bogaars; V J Hearing; A Maizel; H Wanebo
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.